OncoMatch/Clinical Trials/NCT05451771
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
Is NCT05451771 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for al amyloidosis.
Treatment: Venetoclax Oral Tablet, 200 mg · FISH assay · Venetoclax Oral Tablet, 400 mg · Dexamethasone Oral, 10 mg · Dexamethasone Oral, 20 mg · Daratumumab · Bendamustine · Pomalidomide · Ixazomib · Venetoclax MTD with Dexamethasone — The purpose of this study is assess safety, safest dose, and effectiveness of venetoclax in combination with dexamethasone in participants with t(11;14) positive relapsed (comes back) or refractory (did not get better) light chain amyloidosis.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Biomarker criteria
Required: CCND1 t(11;14) translocation
Disease stage
Excluded: Stage MAYO STAGE THREE-B (IIIB) WITH NT-PRO BNP > 8500 PG/ML
Mayo stage three-B (IIIB) with N-terminal pro-hormone B-type natriuretic peptide (NT-Pro BNP) > 8500 pg/mL
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD38 monoclonal antibody
Has received ≥1 prior lines of therapy, including an anti-cluster of differentiation 38 (CD 38) monoclonal antibody
Cannot have received: BCL2 inhibitor
Prior exposure to anti-apoptotic protein B-cell lymphoma 2 (BCL-2) inhibitors
Lab requirements
Cardiac function
New York Heart Association (NYHA) Class III or IV heart failure [excluded]
Patients on renal replacement therapy; New York Heart Association (NYHA) Class III or IV heart failure
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Boston Medical Center · Boston, Massachusetts
- Mayo Clinic Rochester · Rochester, Minnesota
- New York Presbyterian Hospital/Columbia University Irving Medical Center · New York, New York
- Froedtert Hospital & the Medical College of Wisconsin · Milwaukee, Wisconsin
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify